# Pharmacokinetic Effect of Y-3 for Injection on Rosuvastatin Calcium Tablets in Healthy Participants

> **NCT07692685** · PHASE1 · COMPLETED · sponsor: **Neurodawn Pharmaceutical Co., Ltd.** · enrollment: 20 (actual)

## Conditions studied

- Drug Drug Interaction
- Pharmacokinetic Profiles
- Safty

## Interventions

- **DRUG:** Use of rosuvastatin calcium tablet alone or combined with Y-3 for injection

## Key facts

- **NCT ID:** NCT07692685
- **Lead sponsor:** Neurodawn Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2026-05-07
- **Primary completion:** 2026-06-04
- **Final completion:** 2026-06-04
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2026-07-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07692685

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07692685, "Pharmacokinetic Effect of Y-3 for Injection on Rosuvastatin Calcium Tablets in Healthy Participants". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07692685. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*